Experiences with Simplera sync™ all‐in‐one sensors and extended wear infusion sets in adolescents and young adults using the MiniMed ™ 780G : A qualitative study

Résumé fourni par la source

AIMS: To evaluate the real-world user experience of young people (7-25 years) with type 1 diabetes and previously very elevated glycaemia (≥69 mmol/mol) transitioning from the MiniMed™ 780G advanced hybrid closed-loop (AHCL) system with Guardian™ 4 continuous glucose monitoring systems (CGM) and 3-day infusion sets to the upgraded system with Simplera Sync™ all-in-one CGM and 7-day Extended™ wear infusion sets (EIS). METHODS: Qualitative interviews were conducted with 11 participants from the CO-PILOT trial extension phase who had used the upgraded system for at least 4 weeks. Thematic analysis was used to identify aspects of the technology transition that reduced, continued, or did not affect the burden of diabetes care and technology. RESULTS: Participants reported several burden-reducing aspects of the upgraded system, including easier, independent insertion of both sensors and infusion sets, improved device design (slimmer profile, one-piece disposable design), reduced frequency of equipment changes, and decreased psychosocial burden. Aspects with ongoing burden included premature sensor failures, connection issues between pump and sensor, adhesion problems, and concerns about alarm functionality. Trust in the AHCL system remained high across both systems for most participants. CONCLUSION: The transition from Guardian™ 4 and 3-day infusion sets to Simplera Sync™ and EIS was overall positive, with participants reporting enhanced user experience, greater convenience, and improved autonomy. However, challenges with premature sensor failure and alarm functionality were identified at times. These findings highlight the importance of continued technological advancement while maintaining multiple options to accommodate individual needs and preferences.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.